The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / How Do Reduced-Dose Glucocorticoids Plus Rituximab Affect ANCA-Associated Vasculitis?

How Do Reduced-Dose Glucocorticoids Plus Rituximab Affect ANCA-Associated Vasculitis?

October 13, 2021 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Rheumatologists typically treat patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis with an induction dose of glucocorticoids (i.e., 1 mg/kg daily of prednisone) and rituximab.

You Might Also Like
  • Longer Rituximab Therapy Boosts Remission in ANCA-Associated Vasculitis
  • ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab
Explore This Issue
November 2021
Also By This Author
  • Chondrocyte Enlargement Sheds New Light on Cell Volume Regulation

However, a recent clinical trial evaluated the benefits of reduced glucocorticoid dosing during remission induction for patients with ANCA-associated vasculitis. Shunsuke Furuta, MD, PhD, of Chiba University Hospital, Japan, and colleagues examined patients with newly diagnosed ANCA-associated vasculitis without severe glomerulonephritis or alveolar hemorrhage to determine if induction of disease remission could be achieved at six months with a reduced dose (0.5 mg/kg/day) of prednisolone. They found a regimen of reduced-dose glucocorticoids plus rituximab was noninferior to a regimen of high-dose (1 mg/kg/day) glucocorticoids plus rituximab and published the results on June 1 in JAMA.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Other studies have also assessed whether patients with ANCA-associated vasculitis can be effectively treated with lower glucocorticoid doses than are commonly used. Examples:

  1. The ADVOCATE clinical trial evaluated the efficacy of avocapan, a C5a receptor inhibitor, for its ability to induce remission as defined by a Birmingham Vasculitis Activity Score of 0 and no receipt of glucocorticoids for four weeks before week 26, and sustained remission, defined as remission at week 26 and at week 52 and no receipt of glucocorticoids for four weeks before week 52. That trial found avocapan was noninferior at week 26 to high-dose prednisone (cyclophosphamide given intravenously at a dose of 15 mg per kilogram of body weight up to 1.2 g on day 1 and at weeks 2, 4, 7, 10 and 13 or cyclophosphamide orally at a dose of 2 mg per kilogram up to 200 mg per day for 14 weeks) in inducing remission and superior to high-dose prednisone at week 52 in sustaining remission.2
  2. RITAZAREM evaluated patients with relapsing ANCA-associated vasculitis and found that, when combined with rituximab, a reduced-dose prednisone regimen, with a starting dose of 0.5/mg/kg/day, had a similar remission rate as a high-dose regimen of 1 mg/kg/day;3 and
  3. The PEXIVAS clinical trial evaluated whether patients with the most severe ANCA-associated vasculitis had better outcomes with reduced dose or standard glucocorticoid tapering. All patients received oral prednisone or prednisolone at the same dose for the first week. At the start of the second week, the dose in the reduced-dose group was reduced by approximately 50%. The dose in the standard-dose group was tapered more gradually, starting in week 3. At six months, the cumulative dose of oral glucocorticoids in the reduced-dose group was less than 60% of that in the standard-dose group. The study revealed that reduced dose tapering was noninferior to standard tapering with respect to death or end-stage kidney disease.4

New Data Reinforce Message

“Generally speaking, when we, as physicians, deal with a serious life-threatening disease or condition, such as vasculitis, to save our patients lives—and based on our medical training—we usually believe a more aggressive approach or treatment, including using a higher dose of steroids, is the better option for our patients and will give them a higher chance for favorable outcomes,” says Mehrnaz Hojjati, MD, medical director of the Vasculitis Clinic at Loma Linda University Health, California.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: ANCA-Associated Vasculitis, Glucocorticoids, Remission, rituximabIssue: November 2021

You Might Also Like:
  • Longer Rituximab Therapy Boosts Remission in ANCA-Associated Vasculitis
  • ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab
  • Rituximab Receives Label Update for ANCA-Associated Vasculitis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)